腫瘍糖尿病学Q&A　がん患者さんの糖尿病診療マニュアル

出版社： 金芳堂
著者：
発行日： 2020-07-31
分野： 臨床医学：内科  >  糖尿病
ISBN： 9784765318358
電子書籍版： 2020-07-31 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：約3営業日

5,500 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

5,500 円(税込)

購入する

商品紹介

最新知識やエビデンスを可能な限り踏まえつつ、実地臨床でどのようにすればよいのか、第一線で活躍する医師のエキスパート・オピニオンを通して、がん治療中の糖尿病管理に関するベスト・プラクティスをQ&A形式で一冊に集約。若手医師はもちろん、糖尿病専門医のいないがん専門施設で糖尿病管理に奮闘されているがん専門医の先生方にとっても「今日から使える」内容です！

目次

  • I　がんと糖尿病の基礎知識
    第1章　がんと糖尿病の関係
    Q．糖尿病患者さんはがんになりやすいのか？
    Q．糖尿病患者さんのがんを早期発見するにはどのようなことに注意したらよいか？
    Q．糖尿病を合併していることでがんの予後に影響はあるのか？
    Q．膵がんと糖尿病の関係は？
    Q．NASHからの肝がん発症と糖尿病の関係は？

    第2章　糖尿病治療薬
    Q．がんのリスクを増やす糖尿病治療薬はあるのか？
    Q．“がん治療に併用する”という観点では、各種糖尿病治療薬の特徴をどのようにとらえたらよいか？

    第3章　がん患者さん特有の問題
    Q．糖尿病患者さんで特に注意すべき感染症はどのようなものがあるのか？
    Q．がん患者さんに特有の心理とは？
    Q．がん患者さんの栄養管理をどのように行うのか？

    第4章　糖尿病専門医へのコンサルテーション
    Q．がん患者さんに未治療糖尿病が発見された場合、糖尿病専門医への紹介は全例行うべきか？
    　　紹介する場合、事前にやっておくべきことは何か？

    第5章　食事療法
    Q．食事療法として糖質制限食を行ってもよいか？
    　　（がん患者さんが自己判断で糖質を減らしてしまうこともしばしばあるが、どうか？）
    Q．がん患者さんについては糖尿病の食事療法を緩和すべきか？

    第6章　薬物療法
    Q．糖尿病が非専門であるがん治療医でも比較的安全に使える糖尿病治療薬はどのようなものがあるか？
    Q．がん治療で用いられる薬剤で、副作用として血糖値を上昇させるものには何があるか？
    Q．強化インスリン療法とはどのような治療か？
    Q．いわゆるスライディングスケールはどのような場面で使ってよいのか？
    Q．中心静脈栄養を行う際に、インスリンはどのような経路で投与するべきか？

    第7章　検査
    Q．ビグアナイド内服中の症例で、緊急な場合は造影CTを施行してもよいか？
    Q．FDG-PETを行う際の血糖管理や使用する糖尿病治療薬の注意点は？

    II　周術期の血糖管理
    第8章　手術前の血糖管理
    Q．手術可能なHbA1c、血糖値の目安はどのくらいか？
    Q．手術の前に行っておくべき糖尿病合併症検査は？
    Q．手術を行う症例に対してどのようにインスリン治療を行うか？
    Q．血糖コントロールが悪い場合、手術可能なレベルに持っていくまで
    　　どれくらいの期間が必要か？
    Q．経口糖尿病薬のみで血糖コントロールが良好な場合、どの薬剤を内服していても
    　　すぐに手術可能か？それとも必ずインスリン導入をしないといけないのか？
    Q．尿糖陽性は術前血糖コントロールの指標としてどう判断するか？
    　　（SGLT2阻害薬使用例も今後増えることが予想されるため）
    Q．緊急手術が必要な症例が血糖コントロール不良だった場合、
    　　そのまま手術を施行してよいのか？
    Q．糖尿病の重症度と周術期リスクに関連はあるのか？

    第9章　手術後の血糖管理
    Q．胃・食道切除後の血糖コントロールはどのように行うのか？
    Q．膵切除後の血糖管理はどのように行うのか？
    Q．糖尿病患者さんに経腸栄養を使用する際、糖質制限経腸栄養製品（グルセルナなど）
    　　を使用することがあるが、尿ケトンの上昇はどれくらいまで許容できるか？
    Q．胃瘻や腸瘻を使用する際にインスリンはどのように使うのか？
    　　また経口糖尿病薬は使えないのか？
    Q．術後早期から厳格な血糖コントロールを目指すべきか？
    　　術後早期に使う薬剤として、インスリン以外に経口薬を使用してもよいか？
    Q．ICU管理が必要な重症患者において、Harris-Benedictの式ではストレス度が高い場合
    　　エネルギー必要量が増えるが、どのようにエネルギー量の設定を行うか？

    III　がん化学療法中の血糖管理
    第10章　ステロイド投与時の血糖管理
    Q．ステロイド投与による高血糖に対してどのようにインスリン治療を行うか？
    Q．がん化学療法中の血糖コントロールを厳密にしたほうがよいというエビデンスはあるか？
    Q．ステロイドを含むレジメンを短期間だけ行うときでも、必ずインスリン注射による
    　　厳格な管理が必要か？

    第11章　消化器症状が出たときの対応
    Q．糖尿病症例にオランザピン（制吐剤）を使用してよいか？
    Q．抗がん剤治療後に食欲がなくなったときの血糖管理はどのように行うか？
    Q．外来化学療法を行っている糖尿病患者さんにシックデイ対応として
    　　どのような指導を行うか？

    第12章　その他の副作用関連
    Q．糖尿病をもつ症例に、末梢神経障害の副作用を起こし得る抗がん剤を使用してよいか？
    Q．血管新生阻害薬で、心血管イベントなど糖尿病内科医が注意すべきことはあるか？
    Q．インスリン自己注射や、自己血糖測定が抗がん剤の副作用である皮膚障害と
    　　関連することはあるか？

    第13章　免疫チェックポイント阻害薬と（劇症）1型糖尿病
    Q．免疫チェックポイント阻害薬を投与する症例では、どのような検査を行うことで
    　　1型糖尿病（劇症1型を含む）の早期発見につながるか？また患者さんに
    　　注意してもらう自覚症状などはあるか？
    Q．元来2型糖尿病のある症例に免疫チェックポイント阻害薬を投与することで、
    　　劇症1型糖尿病を含む1型糖尿病のような病態をさらに発症することはあるのか？
    Q．1型糖尿病以外の内分泌異常にはどのようなものがあるか？

    IV　がんサバイバー、長期のがん治療が必要なケース
    第14章　がんサバイバー
    Q．がんが一旦治癒、寛解した症例では、どのくらいの目標値で血糖を管理するべきか？
    　　使用してよい糖尿病治療薬は？
    Q．乳がん、前立腺がんなど比較的長期間のがん治療を行う場合の血糖コントロールの目標は？

    第15章　終末期
    Q．終末期では血糖値の目標をどこにおくのか？
    Q．終末期では食事療法をどこまで行うべきか？血糖上昇を緩やかにできる食事内容は？
    Q．終末期でも安全に使える糖尿病治療薬は？
    Q．食事が食べられなくなった場合の血糖降下薬の減量、中止の判断は？
    Q．インスリン治療を行っていた症例はどのように管理するか？

    【Column】
    調整困難な交絡因子
    がん検診の功罪
    血管合併症の評価はどこまで必要か？
    血糖測定方法の差異
    refeeding症候群
    糖尿病がある症例ではステロイドを減量もしくは抜いたレジメンにした方が良いか？
    スピリチュアルケアとしての血糖コントロール

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

[I] がんと糖尿病の基礎知識

P.7 掲載の参考文献
1) Noto H, et al. Significantly increased risk of cancer in patients with diabetes mellitus. Endocr Pract 2011 ; 17 : 616-628.
PubMed
2) 糖尿病と癌に関する委員会. 糖尿病と癌に関する委員会報告. 糖尿病 2013 ; 56 : 374-390.
 
3) 中村二郎, 他. -糖尿病の死因に関する委員会報告-アンケート調査による日本人糖尿病の死因-2001～2010年の10年間, 45,708名での検討-. 糖尿病 2016 ; 59 : 667-684.
 
4) Ranc K, et al. Mortality after cancer among patients with diabetes mellitus : effect of diabetes duration and treatment : (questionable) classification of diabetic patients based on combination of specific glucose-lowering drugs. Reply to Holden SE, Bannister CA, Currie CJ [letter]. Diabetologia 2014 ; 57 : 2003-2004.
 
5) Larsson SC, Wolk A. Diabetes mellitus and incidence of kidney cancer : a metaanalysis of cohort studies. Diabetologia 2011 ; 54 : 1013-1018.
PubMed
6) Sasazuki S, et al. Diabetes mellitus and cancer risk : Pooled analysis of eight cohort studies in Japan. Cancer Sci 2013 ; 104 : 1499-1507.
PubMed
7) Noto H, et al. Significantly increased risk of cancer in diabetes mellitus patients : A meta-analysis of epidemiologic evidence in Asians and non-Asians. J Diabetes 2012 ; 3 : 24-33.
 
8) Yang X, et al. Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes : the Hong Kong diabetes registry. Diabetes 2010 ; 59 : 1254-1260.
 
9) Johnson JA, Bowker SL. Intensive glycaemic control and cancer risk in type 2 diabetes : a meta-analysis of major trials. Diabetologia 2011 ; 54 : 25-31.
PubMed
10) Kobayashi D, et al. Malignancy incidences by glycemic control among diabetic patients. Endocr Connect 2018.
PubMed
11) Takao T, et al. Association between postprandial hyperglycemia at clinic visits and all-cause and cancer mortality in patients with type 2 diabetes : A long-term historical cohort study in Japan. Diabetes Res Clin Pract 2019 ; 148 : 152-159.
PubMed
12) Kobayashi D, et al. Development of malignancies and changes in time-dependent hemoglobin A 1 c among a nondiabetic population : longitudinal analysis. Acta Diabetol 2020 ; 57 : 189-196.
 
13) Noto H, et al. Cancer risk in diabetic patients treated with metformin : A systematic review and meta-analysis. PLoS One 2012 ; 7 : e33411.
PubMed
P.14 掲載の参考文献
1) Hwangbo Y, et al. Incidence of diabetes after cancer development : A Korean national cohort study. JAMA Oncol 2018 ; 4 : 1099-1105.
PubMed
2) がん予防重点健康教育及びがん検診実施のための指針 (平成28年2月4日一部改正). https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000059490.html
 
3) Lee JH, et al. New-onset diabetes patients need pancreatic cancer screening? J Clin Gastroenterol 2012 ; 46 : e58-61.
PubMed
4) Sharma A, et al. Model to determine risk of pancreatic cancer in patients with new-onset diabetes. Gastroenterology 2018 ; 155 : 730-739. e3.
 
P.17 掲載の参考文献
1) Barone BB, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus : a systematic review and meta-analysis. JAMA 2008 ; 300 : 2754-2764.
PubMed
2) Barone BB, et al. Postoperative mortality in cancer patients with preexisting diabetes : systematic review and meta-analysis. Diabetes Care 2010 ; 33 : 931-939.
PubMed
3) Renehan AG, et al. Diabetes and cancer (2) : evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia 2012 ; 55 : 1619-1632.
PubMed
4) Zeng L, et al. Hyperglycaemia confers resistance to chemotherapy on breast cancer cells : the role of fatty acid synthase. Endocr Relat Cancer 2010 ; 17 : 539-551.
PubMed
5) Stein KB, et al. Colorectal cancer outcomes, recurrence, and complications in persons with and without diabetes mellitus : a systematic review and metaanalysis. Dig Dis Sci 2010 ; 55 : 1839-1851.
PubMed
6) Meyerhardt JA, et al. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol 2003 ; 21 : 433-440.
PubMed
7) Snyder CF, et al. Does pre-existing diabetes affect prostate cancer prognosis? A systematic review. Prostate Cancer Prostatic Dis 2010 ; 13 : 58-64.
PubMed
8) van de Poll-Franse LV, et al. Less aggressive treatment and worse overall survival in cancer patients with diabetes : a large population based analysis. Int J Cancer 2007 ; 120 : 1986-1992.
PubMed
9) Viollet B, et al. Cellular and molecular mechanisms of metformin : an overview. Clin Sci (Lond) 2012 ; 122 : 253-270.
PubMed
10) Zhou G, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001 ; 108 : 1167-1174.
PubMed
11) Memmott RM, et al. Metformin prevents tobacco carcinogen--induced lung tumorigenesis. Cancer Prev Res (Phila) 2010 ; 3 : 1066-1076.
PubMed
12) Goodwin PJ, et al. Evaluation of metformin in early breast cancer : a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat 2011 ; 126 : 215-220.
PubMed
P.22 掲載の参考文献
1) Aggarwal G, et al. Prevalence of diabetes mellitus in pancreatic cancer compared to common cancers. Pancreas 2013 ; 42 : 198-201.
PubMed
2) Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 1995 ; 273 : 1605-1609.
PubMed
3) Huxley R, et al. Type II diabetes and pancreatic cancer : a meta-analysis of 36 studies. Br J Cancer 2005 ; 92 : 2076-2083.
PubMed
4) Ben Q, et al. Diabetes mellitus and risk of pancreatic cancer : a meta-analysis of cohort studies. Eur J Cancer 2011 ; 47 : 1928-1937.
PubMed
5) Sasazuki S, et al. Diabetes mellitus and cancer risk : Pooled analysis of eight cohort studies in Japan. Cancer Sci 2013 ; 104 : 1499-1507.
PubMed
6) Calle EE, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003 ; 348 : 1625-1638.
 
7) Lowenfels AB, et al. Pancreatitis and the risk of pancreatic cancer : International Pancreatitis Study Group. N Engl J Med 1993 ; 328 : 1433-1437.
 
8) Pelaez-Luna M, et al. Resectability of presymptomatic pancreatic cancer and its relationship to onset of diabetes : a retrospective review of CT scans and fasting glucose values prior to diagnosis. Am J Gastroenterol 2007 ; 102 : 2157-2163.
PubMed
9) Basso D, at al. Beta-cell function in pancreatic adenocarcinoma. Pancreas 1994 ; 9 : 332-335.
 
10) Pannala R, et al. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 2008 ; 134 : 981-987.
PubMed
11) Gardner TB, et al. The effect of neoadjuvant chemoradiation on cancer-associated diabetes mellitus. Pancreas 2014 ; 43 : 1018-1021.
PubMed
12) Aggarwal G, et al. Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in beta cells and mice. Gastroenterology 2012 ; 143 : 1510-1517.
PubMed
13) Basso D, et al. Pancreatic cancer-derived S-100A8 N-terminal peptide : a diabetes cause? Clin Chim Acta 2006 ; 372 : 120-128.
PubMed
14) Huang H, et al. Novel blood biomarkers of pancreatic cancer-associated diabetes mellitus identified by peripheral blood-based gene expression profiles. Am J Gastroenterol 2010 ; 105 : 1661-1669.
PubMed
15) 日本膵臓学会膵癌診療ガイドライン改訂委員会. 膵癌診療ガイドライン 2016年版. 金原出版, 2016.
 
16) Walter U, et al. Impact of preoperative diabetes on long-term survival after curative resection of pancreatic adenocarcinoma : a systematic review and metaanalysis. Ann Surg Oncol 2014 ; 21 : 1082-1089.
PubMed
17) Yuan C, et al. Survival among patients with pancreatic cancer and long-standing or recent-onset diabetes mellitus. J Clin Oncol 2015 ; 33 : 29-35.
PubMed
18) Tan J, et al. Association of elevated risk of pancreatic cancer in diabetic patients : A systematic review and meta-analysis. Oncol Lett 2017 ; 13 : 1247-1255.
PubMed
P.27 掲載の参考文献
1) 中村二郎, 他. 糖尿病の死因に関する委員会報告 アンケート調査による日本人糖尿病の死因 2001～2010年の10年間, 45,708名での検討. 糖尿病 2016 ; 59 : 667-684.
 
2) 厚生労働省大臣官房統計情報部編. 人口動態統計.
 
3) Wang C, et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus : a systematic review and meta-analysis of cohort studies. Int J Cancer 2012 ; 130 : 1639-1648.
PubMed
4) Karagozian R, et al. Obesity-associated mechanisms of hepatocarcinogenesis. Metabolism 2014 ; 63 : 607-617.
PubMed
5) Nakahara T, et al. Japan study group of nonalcoholic fatty liver D. Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J Gastroenterol 2014 ; 49 : 1477-1484.
 
6) Ballestri S, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol 2016 ; 31 : 936-944.
PubMed
7) Yamada T, et al. Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup. J Gastroenterol Hepatol 2010 ; 25 : 352-356.
PubMed
8) Kawamura Y, et al. Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol 2012 ; 107 : 253-261.
PubMed
9) Yatsuji S, et al. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol 2009 ; 24 : 248-254.
PubMed
P.32 掲載の参考文献
1) 春日雅人, 他. 糖尿病と癌に関する委員会報告. 糖尿病 2013 ; 56 : 374-390.
 
2) Hemkens LG, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues : a cohort study. Diabetologia 2009 ; 52 : 1732-1744.
 
3) Jonasson JM, et al. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 2009 ; 52 : 1745-1754.
PubMed
4) Colhoun GM, et al. Use of insulin glargine and cancer incidence in Scotland : a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009 ; 52 : 1755-1765.
 
5) Currie CJ, et al. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009 ; 52 : 1766-1777.
PubMed
6) McFarland MS, et al. Diabetes mellitus and increased risk of cancer : focus on metformin and the insulin analogs. Pharmacotherapy 2010 ; 30 : 1159-1178.
PubMed
7) Smith U, et al. Does diabetes therapy influence the risk of cancer? Diabetologia 2009 ; 52 : 1699-1708.
PubMed
8) Edoardo M, et al. Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 2010 ; 33 : 1997-2003.
 
9) The ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012 ; 367 : 319-328.
PubMed
10) Evans JM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005 ; 330 : 1304-1305.
PubMed
11) Noto H, et al. Cancer risk in diabetic patients treated with metformin : a systematic review and meta-analysis. PLoS One 2012 ; 7 : e33411.
PubMed
12) Lewis JD, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone : interim report of a longitudinal cohort study. Diabetes Care 2011 ; 34 : 916-922.
PubMed
13) Lewis JD, et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA 2015 ; 314 : 265-277.
PubMed
14) Tuccori M, et al. Pioglitazone use and risk of bladder cancer : population based cohort study. BMJ 2016 ; 352 : i1541.
PubMed
15) Prost S, et al. Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists. Nature 2015 ; 525 : 180-183.
 
16) Soranna D, et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes : a meta-analysis. Oncologist 2012 ; 17 : 813-822.
PubMed
17) Chang CH, et al. Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus. J Clin Endocrinol Metab 2012 ; 97 : E1170-1175.
PubMed
18) Yang X, et al. Use of sulphonylurea and cancer in type 2 diabetes-The Hong Kong Diabetes Registry. Diabetes Res Clin Pract 2010 ; 90 : 343-351.
 
19) Monami M, et al. Sulphonylureas and cancer : a case-control study. Acta Diabetol 2009 ; 46 : 279-284.
 
20) Elashoff M, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011 ; 141 : 150-156.
PubMed
21) Grenn JB, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015 ; 373 : 232-242.
 
22) White WB, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013 ; 369 : 1327-1335.
PubMed
23) Scirica BM, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013 ; 369 : 1317-1326.
PubMed
24) Pfeffer MA, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015 ; 373 : 2247-2257.
PubMed
25) Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016 ; 375 : 311-322.
PubMed
26) Wang H, et al. A replication-defective human cytomegalovirus vaccine elicits humoral immune responses analogous to those with natural infection. Sci Transl Med 2016 ; 8 : 334-351.
 
27) Piccinni C, et al. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 2011 ; 34 : 1369-1371.
PubMed
28) Tseng CH. Diabetes and risk of bladder cancer : A study using the national health insurance database in Taiwan. Diabetologia 2011 ; 54 : 2009-2015.
PubMed
29) Scafoglio C, et al. Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci USA 2015 ; 112 : E4111-4119.
PubMed
P.38 掲載の参考文献
1) Orgel E, et al. The links between insulin resistance, diabetes, and cancer. Curr Diab Rep 2013 ; 13 : 213-222.
PubMed
2) 日本糖尿病学会. 糖尿病専門医研修ガイドブック. 改訂第7版, p406, 診断と治療社, 2017.
 
3) Quillen DM, Kuritzky L. Type 2 diabetes management : a comprehensive clinical review of oral medications. Compr Ther 2002 ; 28 : 50-61.
PubMed
4) Misbin RI, et al. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998 ; 338 : 265-266.
PubMed
5) 日本糖尿病学会. 「ビグアナイド薬の適正使用に関する委員会」から. メトホルミンの適正使用に関するRecommendation. 改訂2020年3月18日. [http://www.jds.or.jp/modules/important/index.php?content_id=20]
 
6) Loke YK, et al. Long-term use of thiazolidinediones and fractures in type 2 diabetes : a meta-analysis. CMAJ 2009 ; 180 : 32-39.
PubMed
7) 日本糖尿病学会. 「SGLT 2 阻害薬の適正使用に関する委員会」から. SGLT 2 阻害薬の適正使用に関するRecommendation. 改訂2016年5月12日. [http://www.fa.kyorin.co.jp/jds/uploads/recommendation_SGLT2.pdf]
 
P.45 掲載の参考文献
1) Schuetz P, et al. Diabetes and sepsis : preclinical findings and clinical relevance. Diabetes Care 2011 ; 34 : 771-778.
PubMed
2) 米田真康, 他. 糖尿病患者における感染症の特徴及びその対策. 糖尿病 2007 ; 50 : 137-143.
 
3) Rao Kondapally Seshasai S, et al : Diabetes mellitus, fasting glucose, and risk of cause?specific death. N Engl J Med 2011 ; 364 : 829-841.
PubMed
4) Benfield T, et al. Influence of diabetes and hyperglycemia on infectious disease hospitalization and outcome. Diabetologia 2007 ; 50 : 549-554.
PubMed
5) Kornum JB, et al. Diabetes, glycemic control, and risk of hospitalization with pneumonia : a population-based case-control study. Diabetes care 2008 ; 31 : 1541-1545.
PubMed
6) McAlister FA, et al. The relation between hyperglycemia and outcomes in 2471 patients admitted to the hospital with community acquired pneumonia. Diabetes Care 2005 ; 28 : 810-815.
 
7) Lopez-de-Andres A, et al. Hospitalization with community-acquired pneumonia among patients with type 2 diabetes : an observational population-based study in Spain from 2004 to 2013. BMJ Open 2017 ; 7 : e013097.
PubMed
8) 一般社会法人日本呼吸器学会. 成人肺炎診療ガイドライン 2017.
 
9) Goeijenbier M, et al. Benefits of flu vaccination for persons with diabetes mellitus : a review. Vaccine 2017 ; 35 : 5095-5101.
PubMed
10) Standards of Medical Care in Diabetes-2018 Diabetes Care 2018 Jan ; 41 : S1-S2. https://doi.org/10.2337/dc18-Sint01
 
11) Hirji I, et al. Incidence of genital infection among patients with type 2 diabetes in the UK General Practice Research Database. J Diabetes Complications 2012 ; 26 : 501-505.
PubMed
12) Suzanne G, et al. Genital and urinary tract infections in diabetes : Impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract 2014 ; 103 : 373-381.
 
13) Suzanne E. Urinary tract infections in patients with diabetes mellitus : Epidemiology, pathogenesis and treatment. Int J Antimicrob Agents 2008 ; 31 : S54-57.
 
14) https://janis.mhlw.go.jp/report/open_report/2017/3/1/ken_Open_Report_201700.pdf
 
15) Nicolle LE, et al. Clinical practice guideline for the management of asymptomatic bacteriuria : 2019 update by the infectious diseases society of america. Clin Infect Dis 2019 ; 68 : 1611-1615.
 
16) Anton YP. Common infections in diabetes : pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev 2007 ; 23 : 3 -13.
 
17) Gupta S, et al. Infections in diabetes mellitus and hyperglycemia. Infect Dis Clin North Am 2007 ; 21 : 617-638.
PubMed
P.52 掲載の参考文献
1) 高橋三郎, 他, 監訳. DSM-5 精神疾患の分類と診断の手引き. 医学書院, 2014.
 
2) Yamauchi T, et al. Death by suicide and other externally caused injuries following a cancer diagnosis : the Japan Public Health Center-based Prospective Study. Psychooncology 2014 ; 23 : 1034-1041.
PubMed
3) 「がんの社会学」に関する研究グループ. がん体験者の悩みや負担等に関する実態調査報告書 がんと向き合った4054人の声, 2013.
 
4) 清水研. 「見逃せない病態と対処法」サイコオンコロジー. CANCER BOARD 乳癌 2014 ; 6 : 159-162.
 
5) Akizuki N, et al. Development of an impact thermometer for use in combination with the distress thermometer as a brief screening tool for adjustment disorders and/or major depression in cancer patients. J Pain Symptom Manage 2005 ; 29 : 91-99.
PubMed
P.58 掲載の参考文献
1) Tan BH, et al. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 2009 ; 15 : 6973-6979.
PubMed
2) 日本栄養士会, 監訳. 国際標準化のための栄養ケアプロセス用語マニュアル. 初版, 第一出版, 2012.
 
3) 神谷しげみ, 他. 同種造血幹細胞移植後早期の至適エネルギー投与量に関する研究. 日本静脈経腸栄養学会雑誌 2011 ; 26 : 103-110.
 
4) Hill GL. Perioperative nutrition. Disorders of Nutrition and Metabolism in Clinical Surgery ; Understanding and Management 1992.
 
5) 国立がん情報センターがん情報サービス https://ganjoho.jp/public/index.html
 
P.64 掲載の参考文献
1) 日本糖尿病学会, 作成. 日本医師会, 監修. かかりつけ医から糖尿病専門医・専門医療機関への紹介基準. (日本糖尿病学会ホームページ, 2019年11月21日確認) http://www.fa.kyorin.co.jp/jds/uploads/2018-02_referralstandard_jds.pdf
 
2) 日本糖尿病学会, 編著. インスリンによる治療. 糖尿病診療ガイドライン 2019, pp93-105, 南江堂, 2019.
 
3) 免疫チェックポイント阻害薬使用患者における1型糖尿病の発症に関するRecommendation (2016年5月18日). (日本糖尿病学会ホームページ, 2019年11月21日確認) http://www.fa.kyorin.co.jp/jds/uploads/recommendation_nivolumab.pdf
 
P.74 掲載の参考文献
1) Adiamah A, et al. The impact of preoperative immune modulating nutrition on outcomes in patients undergoing surgery for gastrointestinal cancer : A systematic review and meta-analysis. Ann Surg 2019 ; 270 : e127-128.
 
2) McKay BP, et al. Pre-operative vs. peri-operative nutrition supplementation in hepatic resection for cancer : A systematic review. Nutr Cancer 2019 ; 71 : 179-198.
 
3) Thanikachalam K, Khan G. Colorectal cancer and nutrition. Nutrients 2019 ; 11 : E164.
 
4) Yang F, et al. Effects of early postoperative enteral nutrition versus usual care on serum albumin, prealbumin, transferrin, time to first flatus and postoperative hospital stay for patients with colorectal cancer : A systematic review and metaanalysis. Contemp Nurse 2018 ; 54 : 561-577.
PubMed
5) Westhoff E, et al. Body mass index, diet-related factors, and bladder cancer prognosis : A systematic review and meta-analysis. Bladder Cancer 2018 ; 4 : 91-112.
PubMed
6) Schwingshackl L, et al. Adherence to Mediterranean diet and risk of cancer : An updated systematic review and meta-analysis. Nutrients 2017 ; 9 : E1063.
 
7) Feinberg J, et al. Nutrition support in hospitalized adults at nutritional risk. Cochrane Database Syst Rev 2017 ; 5 : CD011598.
PubMed
8) Dinu M, et al. Mediterranean diet and multiple health outcomes : An umbrella review of meta-analysis of observational studies and randomised trials. Eur J Clin Nutr 2018 ; 72 : 30-43.
PubMed
9) Arends J, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr 2017 ; 36 : 11-48.
PubMed
10) Zhao XF, et al. Enteral nutrition versus parenteral nutrition after major abdominal surgery in patients with gastrointestinal cancer : A systematic review and metaanalysis. J Investig Med 2016 ; 64 : 1061-1074.
PubMed
11) Van Dalen EC, et al. Low bacterial diet versus control diet to prevent infection in cancer patients treated with chemotherapy causing episodes of neutropenia. Cochrane Database Syst Rev 2016 ; 4 : CD006247.
PubMed
12) Chow R, et al. Enteral and parenteral nutrition in cancer patients : A systematic review and meta-analysis. Ann Palliat Med 2016 ; 5 : 30-41.
PubMed
13) Grosso G, et al. A comprehensive meta-analysis on evidence of Mediterranean diet and cardiovascular disease : Are individual components equal? Crit Rev Food Sci Nutr 2017 ; 57 : 3218-3232.
PubMed
14) Sonbol MB, et al. The effect of a neutropenic diet on infection and mortality rates in cancer patients : A meta-analysis. Nutr Cancer 2015 ; 67 : 1230-1238.
PubMed
15) Van Blarigan EL, Meyerhardt JA. Role of physical activity and diet after colorectal cancer diagnosis. J Clin Oncol 2015 ; 33 : 1825-1834.
PubMed
16) Maderuelo-Fernandez JA, et al. Effectiveness of interventions applicable to primary health care settings to promote Mediterranean diet or healthy eating adherence in adults : A systematic review. Prev Med 2015 ; 76 : S39-S55.
PubMed
17) Stacey FG, et al. A systematic review and meta-analysis of social cognitive theorybased physical activity and/or nutrition behavior change interventions for cancer survivors. J Cancer Surviv 2015 ; 9 : 305-338.
PubMed
18) Bakker OJ, et al. Timing of enteral nutrition in acute pancreatitis : Meta-analysis of individuals using a single-arm of randomised trials. Pancreatology 2014 ; 14 : 340-346.
PubMed
19) Xing MY, et al. Effect of low-fat diet on breast cancer survival : A meta-analysis. Asian Pac J Cancer Prev 2014 ; 15 : 1141-1144.
PubMed
20) Naska A, Trichopoulou A. Back to the future : The Mediterranean diet paradigm. Nutr Metab Cardiovasc Dis 2014 ; 24 : 216-219.
 
21) Van Dalen EC, et al. Low bacterial diet versus control diet to prevent infection in cancer patients treated with chemotherapy causing episodes of neutropenia. Cochrane Database Syst Rev 2012 ; CD006247.
PubMed
22) Koretz RL, et al. Does enteral nutrition affect clinical outcome? A systematic review of the randomized trials. Am J Gastroenterol 2007 ; 102 : 412-429.
PubMed
23) Braunschweig CL, et al. Enteral compared with parenteral nutrition : A metaanalysis. Am J Clin Nutr 2001 ; 74 : 534-542.
PubMed
24) Ishikawa-Takata K, et al. Physical activity level in healthy free-living Japanese estimated by doubly labelled water method and international physical activity questionnaire. Eur J Clin Nutr 2008 ; 62 : 885-891.
PubMed
25) Yoshimura E, et al. Assessment of energy expenditure using doubly labeled water, physical activity by accelerometer and reported dietary intake in Japanese men with type 2 diabetes : A preliminary study. J Diabetes Investig 2019 ; 10 : 318-321.
PubMed
26) Moses AW, et al. Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n- 3 fatty acids. Br J Cancer 2004 ; 90 : 996-1002.
 
27) Warburg O. On the origin of cancer cells. Science 1956 ; 123 : 309-314.
PubMed
28) Caso J, et al. The effect of carbohydrate restriction on prostate cancer tumor growth in a castrate mouse xenograft model. Prostate 2013 ; 73 : 449-454.
 
29) Morscher RJ, et al. Inhibition of neuroblastoma tumor growth by ketogenic diet and/or calorie restriction in a CD 1 -Nu mouse model. PLoS One 2015 ; 10 : e0129802.
 
30) Thompson HJ, et al. Impact of weight loss on plasma leptin and adiponectin in overweight-to-obese post menopausal breast cancer survivors. Nutrients 2015 ; 7 : 5156-5176.
PubMed
31) Mazidi M, et al. Lower carbohydrate diets and all-cause and cause-specific mortality : A population-based cohort study and pooling of prospective studies. Eur Heart J 2019 ; 40 : 2870-2879.
PubMed
32) Song M, et al. Low-carbohydrate diet score and macronutrient intake in relation to survival after colorectal cancer diagnosis. JNCI Cancer Spectr 2018 ; 2 : pky077.
PubMed
33) Yakovenko A, et al. Molecular therapeutic strategies targeting pancreatic cancer induced cachexia. World J Gastrointest Surg 2018 ; 10 : 95-106.
PubMed
34) Zick SM, et al. Pros and cons of dietary strategies popular among cancer patients. Oncology 2018 ; 32 : 542-547.
PubMed
35) Weigl J, et al. Can nutrition lower the risk of recurrence in breast cancer? Breast Care 2018 ; 13 : 86-91.
PubMed
36) Soldati L, et al. The influene of diet on anti-cancer immune responsiveness. J Transl Med 2018 ; 16 : 75.
 
37) Lin PH, et al. An update of research evidence on nutrition and prostate cancer. Urol Oncol 2019 ; 37 : 387-401.
PubMed
38) Kato I, et al. Differential effects of patient-related factors on the outcome of radiation therapy for rectal cancer. J Radiat Oncol 2016 ; 5 : 279-286.
PubMed
39) Pedersen AN, et al. Health effects of protein intake in healthy adults : A systematic literature review. Food Nutr Res 2013 ; 57 : 21245.
PubMed
40) Nilsson LM, et al. Low-carbohydrate, high-protein score and mortality in a northern Swedish population-based cohort. Eur J Clin Nutr 2012 ; 66 : 694-700.
 
41) Seyfried TN, et al. Is the restricted ketogenic diet a viable alternative to the standard of care for managing malignant brain cancer? Epilepsy Res 2012 ; 100 : 310-326.
 
42) Fung TT, et al. Low-carbohydrate diets and all-cause and cause-specific mortality : Two cohort studies. Ann Intern Med 2010 ; 153 : 289-298.
PubMed
43) Trichopoulou A, et al. Low-carbohydrate-high-protein diet and long-term survival in a general population cohort. Eur J Clin Nutr 2007 ; 61 : 575-581.
 
44) 古川健司, 他. ステージ IV 進行再発大腸がん, 乳がんに対する修正MCTケトン食による安全性と有効性の評価 (pilot study). 日本静脈経腸栄養学会雑誌 2017 ; 32 : 1154-1161.
 
45) 金子哲也. 進行乳頭部癌術後再発例に対するケトン食療法併用の集学的治療の経験. 東三医学会誌 2018 ; 40 : 19-24.
 
46) 古川健司, 他. ステージ IV 進行再発大腸癌に対し修正MCTケトン食を1年間併用した化学療法の臨床効果に関する検討. 日本静脈経腸栄養学会雑誌 2018 ; 33 : 1139-1146.
 
P.81 掲載の参考文献
1) Yamada S, et al. Dietary approaches for Japanese patients with diabetes : A systematic review. Nutrients 2018 ; 10 : E1080.
 
2) Yamada Y, et al. A non-calorie restricted low-carbohydrate diet is effective as an alternative therapy for patients with type 2 diabetes. Intern Med 2014 ; 53 : 13-19.
PubMed
3) Sato J, et al. A randomized controlled trial of 130g/day low-carbohydrate diet in type 2 diabetes with poor glycemic control. Clin Nutr 2017 ; 36 : 992-1000.
 
4) Yabe D, et al. Sodium-glucose co-transporter 2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes : A randomized, open-label, 3 -arm parallel comparative, exploratory study. Diabetes Obes Metab 2017 ; 19 : 739-743.
 
5) Ley SH, et al. Prevention and management of type 2 diabetes : Dietary components and nutritional strategies. Lancet 2014 ; 383 : 1999-2007.
PubMed
6) Davies MJ, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018 ; 41 : 2669-2701.
 
7) Evert AB, et al. Nutrition therapy recommendations for the management of adults with diabetes. Diabetes Care 2013 ; 36 : 3821-3842.
 
8) Evert AB, et al. Nutrition therapy for adults with diabetes or prediabetes : A consensus report. Diabetes Care 2019 ; 42 : 731-754.
 
9) Arends J, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr 2017 ; 36 : 11-48.
PubMed
10) Mann JI, et al. Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus. Nutr Metab Cardiovasc Dis 2004 ; 14 : 373-394.
 
11) American Diabetes Association. Diabetes care in the hospital. Diabetes Care 2019 ; 42 : S173-S181.
PubMed
12) American Diabetes Association. Older adults. Diabetes Care 2019 ; 42 : S139-S147.
PubMed
13) 日本糖尿病学会. ライフステージごとの糖尿病. In 糖尿病治療ガイド 2018-2019. pp98-103, 文光堂, 2018.
 
14) Ranjan A, et al. Short-term effects of a low carbohydrate diet on glycaemic variables and cardiovascular risk marker in patients with type 1 diabetes : A randomized open-label crossover trial. Diabetes Obes Metab 2017 ; 19 : 1479-1484.
 
15) Schmidt S, et al. Low-versus high carbohydrate diet in type 1 diabetes : A 12-week randomized open-label crossover study. Diabetes Obes Metab 2019 ; 21 : 1680-1688.
PubMed
16) Souto DL, et al. Impact of advanced and basic carbohydrate counting methods on metabolic control in patients with type 1 diabetes. Nutrition 2014 ; 30 : 286-290.
PubMed
P.89 掲載の参考文献
1) 日本糖尿病学会, 編. 糖尿病治療ガイド 2018-2019. pp54-55, 文光堂, 2018.
 
2) 岩岡秀明. 経口血糖降下薬選択のアプローチ. In : 岩岡秀明, 栗林伸一 (編著). ここが知りたい! 糖尿病診療ハンドブック Ver.4. pp58-69, 中外医学社, 2019.
 
P.94 掲載の参考文献
1) 日本糖尿病学会・日本内分泌学会.免疫チェックポイント阻害薬による1型糖尿病 http://www.fa.kyorin.co.jp/jds/uploads/imp_201811_type1-dm.pdf
 
2) Yamaguchi M, et al. Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death- 1 therapy. Diabetol Int 2019 ; 10 : 58-66.
 
3) 日本糖尿病学会. 劇症1型糖尿病の診断基準. http://www.jds.or.jp/modules/study/index.php?content_id=4#std2012
 
P.98 掲載の参考文献
1) 日本糖尿病学会, 編. 糖尿病治療ガイド 2018-2019. pp61-62, 文光堂, 2018.
 
P.103 掲載の参考文献
1) Hirsch IB. Sliding scale insulin-Time to stop sliding. JAMA 2009 ; 301 : 213-214.
PubMed
P.109 掲載の参考文献
1) 菅谷量俊, 他. 高カロリー輸液バッグ輸液セットにおけるインスリンの吸着および吸着抑制についての検討. Pharm Tech Jap 1993 ; 9 : 825-830.
 
2) 日本糖尿病学会, 編著. 糖尿病専門医研修ガイドブック. 改定第7版, pp388-395, 診断と治療社, 2017.
 
P.112 掲載の参考文献
1) Lipska KJ, et al. Modifying prescribing guidelines by petitioning the FDA : The metformin experience. Circulation 2016 ; 134 : 1405-1408.
 
2) van der Molen AJ, et al. Post-contrast acute kidney injury. Part 2 : risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients : Recommendations for updated ESUR contrast medium safety committee guidelines. Eur Radiol 2018 ; 28 : 2856-2869.
PubMed
P.116 掲載の参考文献
1) https://www.acr.org/-/media/ACR/Files/Practice-Parameters/FDG-PET-CT.pdf?laen
 
2) Boellaard R, et al. FDG PET/CT : EANM procedure guidelines for tumour imaging : version 2.0. Eur J Nucl Med Mol Imaging 2015 ; 42 : 328-354.
 
3) Hamidizadeh R, et al. Metformin discontinuation prior to FDG PET/CT : A randomized controlled study to compare 24- and 48-hour bowel activity. Radiology 2018 ; 289 : 418-425.
PubMed
4) McCreight LJ, et al. Metformin and the gastrointestinal tract. Diabetologia 2016 ; 59 : 426-435.
PubMed

[II] 周術期の血糖管理

P.120 掲載の参考文献
1) 一般社団法人日本糖尿病学会編, 著. 糖尿病専門医研修ガイドブック, 改訂第7版. p388, 診断と治療社, 2017.
 
2) The Diabetes Control and Complications Trial Research Group. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 1998 ; 116 : 874-886.
 
P.123 掲載の参考文献
1) 山田信博, 他. 糖尿病における血管合併症の発症予防と進展抑制に関する研究 (JDCS). pp38-53, 平成18年度総括研究報告書, 厚生労働科学研究費補助金臨床研究基盤整備推進研究事業, 2007.
 
P.136 掲載の参考文献
1) Salpeter SR, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010 ; CD002967.
 
2) Qiu H, et al. Ketosis and diabetic ketoacidosis in response to SGLT 2 inhibitors : Basic mechanisms and therapeutic perspectives. Diabetes Metab Res Rev. Diabetes Metab Res Rev 2017 ; 33.
PubMed
P.139 掲載の参考文献
1) DeFronzo RA, et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care 2013 ; 36 : 3169-3176.
PubMed
2) 森野勝太郎, 他, 外来2型糖尿病患者の24時間尿糖排泄量を再考する. 糖尿病 2015 : 第58巻.
 
3) 日本糖尿病学会, 編著. 糖尿病専門医研修ガイドブック. 改訂第7版, 診断と治療社, 2017.
 
4) The Joint British Diabetes Societies for inpatient care. Management of adults with diabetes undergoing surgery and elective procedures : improving standards. Revised March 2016. https://www.diabetes.org.uk/professionals/position-statements-reports/specialistcare-for-children-and-adults-and-complications/management-of-adults-withdiabetes-undergoing-surgery-and-elective-procedures-improving-standards
 
5) National Academies of Sciences, Engineering, and Medicine. Dietary Reference Intakes Tables and Application. http://nationalacademies.org/hmd/Activities/Nutrition/SummaryDRIs/DRI-Tables.aspx
 
6) Puckrin R, et al. SGLT- 2 inhibitors and the risk of infections : a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol 2018 ; 55 : 503-514.
PubMed
7) Dave CV, et al. Sodium-glucosecotransporter-2 inhibitors and the risk for severe urinary tract infections. A population-based cohort study. Ann Intern Med 2019 ; 171 : 248-256.
 
8) Zasloff M. Why are diabetics prone to kidney infections? J Clin Invest 2018 ; 128 : 5213-5215.
PubMed
9) Qiu H, et al. Ketosis and diabetic ketoacidosis in response to SGLT 2 inhibitors : Basic mechanisms and therapeutic perspectives. Diabetes Metab Res Rev 2017 ; 33.
PubMed
P.142 掲載の参考文献
1) Frisch A, et al. Prevalence and clinical outcome of hyperglycemia in the perioperative period in noncardiac surgery. Diabetes Care 2010 ; 33 : 1783-1788.
PubMed
2) Kwon S, et al. Importance of perioperative glycemic control in general surgery : a report from the surgical care and outcome assessment program. Ann Surg 2013 ; 257 : 8 -14.
 
3) Hui ML, et al. Protocol-directed insulin infusion sliding scales improve perioperative hyperglycaemia in critical care. Perioper Med (Lond) 2012 ; 1 : 1-10.
PubMed
4) Health and Social Care Information Centre. National Diabetes Inpatient Audit (NaDIA) 2017. https://digital.nhs.uk/data-and-information/publications/statistical/nationaldiabetes-inpatient-audit/national-diabetes-inpatient-audit-nadia-2017
 
P.147 掲載の参考文献
1) 平成28年国民健康・栄養調査報告. https://www.mhlw.go.jp/bunya/kenkou/eiyou/h28-houkoku.html
 
2) Kwon S, et al. Importance of perioperative glycemic control in general surgery : a report from the surgical care and outcomes assessment program. Ann Surg 2013 ; 257 : 8 -14.
 
3) Collier B, et al. Glucose control and the inflammatory response. Nutr Clin Pract 2008 ; 23 : 3 -15.
 
4) NHS Digital. National Diabetes Inpatient Audit (NaDIA) -2017. NHS, 2018. https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetesinpatient-audit/nationaldiabetes-inpatient-audit-nadia-2017
 
5) Nirantharakumar K, et al. Hypoglycaemia is associated with increased length of stay and mortality in people with diabetes who are hospitalized. Diabetic Med 2012 ; 29 : e445-448.
PubMed
6) The NICE-SUGAR study investigators. Hypoglycemia and risk of death in critically ill patients. N Engl J Med 2012 ; 367 : 1108-1118.
 
7) van den Boom W, et al. Effect of A 1 C and glucose on postoperative mortality in noncardiac and cardiac surgeries. Diabetes Care 2018 ; 41 : 782-788.
 
8) Frisch A, et al. Prevalence and clinical outcome of hyperglycemia in the perioperative period in noncardiac surgery. Diabetes Care 2010 ; 33 : 1783-1788.
PubMed
9) Underwood P, et al. Preoperative A 1 C and clinical outcomes in patients with diabetes undergoing major noncardiac surgical procedures. Diabetes Care 2014 ; 37 : 611-616.
 
10) Kotagal M, et al. Perioperative hyperglycemia and risk of adverse events among patients with and without diabetes. Ann Surg 2016 ; 261 : 97-103.
 
11) Yong PH, et al. The presence of diabetes and higher HbA1c are independently associated with adverse outcomes after surgery. Diabetes Care 2018 ; 41 : 1172-1179.
PubMed
12) Rollins KE, et al. Systematic review of the impact of HbA 1 c on outcomes following surgery in patients with diabetes mellitus. Clin Nutr 2016 ; 35 : 308-316.
 
13) Dhatariya K. Should inpatient hyperglycaemia be treated? BMJ 2013 ; 346 : f134.
PubMed
14) Furnary AP. Clinical benefits of tight glycaemic control : Focus on the perioperative setting. Best Pract Res Clin Anaesthesiol 2009 ; 23 : 411-420.
PubMed
15) Wallia A, et al. Glycemic control reduces infections in post-liver transplant patients : Results of a prospective, randomized study. J Clin Endocrinol Metab 2017 ; 102 : 451-459.
PubMed
16) Martin ET, et al. Diabetes and risk of surgical site infection : A systematic review and meta-analysis. Infect Control Hosp Epidemiol 2016 ; 37 : 88-99.
PubMed
17) Wang YY, et al. Postoperative tight glycemic control significantly reduces postoperative infection rates in patients undergoing surgery : A meta-analysis. BMC Endocr Disord 2018 ; 18 : 42.
PubMed
18) Hackett NJ, et al. ASA class is a reliable independent predictor of medical complications and mortality following surgery. Int J Surg 2015 ; 18 : 184-190.
PubMed
19) Ichai C, et al. Acute kidney injury in the perioperative period and in intensive care units (excluding renal replacement therapies). Anaesth Crit Care Pain Med 2016 ; 35 : 151-165.
PubMed
P.154 掲載の参考文献
1) Lichter SB, et al. Effect of adrenergic agents on post-gastrectomy hyperglycemia. Diabetes 1975 ; 24 : 1005-1010.
 
2) 大島行彦, 他. 胃切除後患者に対するアカルボースの有用性. 日消外会誌 1997 ; 30 : 433-438.
 
3) Hasegawa T, et al. Long-term effect of alpha-glucosidase inhibitor on late dumping syndrome. J Gastroenterol Hepatol 1998 ; 12 : 1201-1206.
PubMed
4) Li P, et al. Metformin use and its effect on gastric cancer in patients with type 2 diabetes : A systematic review of observational studies. Oncol Lett 2018 ; 15 : 1191-1199.
PubMed
5) Kurihara K, et al, Effectiveness of sitagliptin in a patients with late dumping syndrome after total gastrectomy. Diabetes Metab Syndr 2018 ; 12 : 203-206.
 
6) Boshier PR, et al. Dumping syndrome after esophagectomy : a systematic review of the literature. Dis Esophagus 2017 ; 30 : 1 -9.
 
7) 須藤峻章, 他. 食道癌手術後における糖代謝と膵内分泌機能に関する検討. 日消外会誌 1982 ; 154 : 1881-1886.
 
P.160 掲載の参考文献
1) 米村豊, 他. 膵大量切除後の残存膵内分泌機能. 日本外科学会雑誌 1981 ; 82 : 671-680.
 
2) Frey CF, et al. Pancreatectomy for chronic pancreatitis. Ann Surg 1976 ; 184 : 403-410.
PubMed
3) Kirstin MJ, Eijck CH. New-onset diabetes after distal pancreatectomy : A systematic review. Ann Surg 2015 ; 261 : 854-861.
 
4) 大橋計彦, 他. 粘液産生膵癌の4例-特異な十二指腸乳頭所見を中心として-. Progress of Digestive Endoscopy 1982 ; 20 : 348-351.
 
5) Tanaka M, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006 ; 6 : 17-32.
PubMed
6) Hwang DW, et al. Clinicopathologic analysis of surgically proven intraductal papillary mucinous neoplasms of the pancreas in snuh : A 15-year experience at a single academic institution. Langenbacks Arch Surg 2012 : 397 : 93-102.
 
7) Suzuki Y, et al. Cystic neoplasm of the pancreas : A Japanese multiinstitutional study of intraductal papillary mucinous tumor and mucinous cystic tumor. Pancreas 2004 ; 28 : 241-246.
PubMed
8) Weinberg BM, et al. Asymptomatic pancreatic cystic neoplasms : Maximizing survival and quality of life using markov-based clinical nomograms. Gastroenterology 2010 ; 138 : 531-540.
PubMed
9) 高池浩子, 他. 膵管内乳頭粘液性腫瘍 (IPMN) 術後の糖代謝の経過についての検討. 東京女子医科大学雑誌 2017 ; 87E : 192-197.
 
P.166 掲載の参考文献
1) Mensink RP, Katan MB. Effect of monounsaturated fatty acids versus complex carbohydrates on high-density lipoproteins in healthy men and women. Lancet 1987 ; 1 : 122-125.
PubMed
2) 櫻井洋一, 他. 高一価不飽和脂肪酸経腸栄養剤の糖代謝, 脂質代謝, 栄養状態に対する長期的投与効果. 外科と代謝・栄養 2003 ; 37 : 33-43.
 
3) Ella M, et al. Enteral nutritional support and use of diabetes-specific formulas for patients with diabetes. Diabetes Care 2005 ; 28 : 2267-2279.
 
4) Vanschoonbeek K, et al. Slowly digestible carbohydrate sources can be used to attenuate the postprandial glycemic response to the ingestion of diabetes specific enteral formulas. Diabetes Educ 2009 ; 35 : 631-640.
 
5) Mayr P, et al. Metabolic control in type 2 diabetes tube fed patients after brain damage during long-term treatment with a new low carbohydrate, high monounsaturated fatty acid containing enteral formula versus standard-like formula : a randomized, prospective controlled, double blind multicenter trial. Clin Nutr 2005 ; 23 : 1497-1498.
 
6) Zuccoli G, et al. Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet : Case Report. Nutr Metab (Lond) 2005 ; 7 : 33.
 
7) 新垣真智子. タピオンにて血糖コントロールが良好となった経腸栄養施行中の糖尿病患者の1例. 栄養評価と治療 2003 ; 20 : 529-531.
 
P.173 掲載の参考文献
1) Pancorbo-Hidalgo PL, et al. Complications associated with enteral nutrition by nasogastric tube in an internal medicine unit. J Clin Nurs 2001 ; 10 : 482-490.
 
2) Arinzon Z, et al. Prevalence of diabetes mellitus in elderly patients received enteral nutrition long-term care service. Arch Gerontol Geriatr 2008 ; 47 : 383-393.
PubMed
3) Korytkowski MT, et al. Insulin therapy and glycemic control in hospitalized patients with diabetes during enteral nutrition therapy. Diabetes Care 2009 ; 32 : 594-596.
PubMed
4) 山崎好美, 他. 経管栄養剤の注入速度と血糖値の推移. 日看技会誌 2007 ; 6 : 18-22.
 
5) 笠倉至言, 他. 経腸経管栄養を受ける急性期脳卒中患者の高血糖に対する持続血糖測定. BRAIN and NERVE 2018 ; 70 : 849-855.
 
6) 森豊, 他. CGMを用いて評価した糖尿病患者の24時間血糖変動に 及ぼす低 GI (Glycemic Index) ・GL (Glycemic Load) 流動食と低GI流動食の比較. 静脈経腸栄養 2011 ; 26 : 57-63.
 
7) 高田俊之, 他. 脳卒中発症後に重度嚥下障害を伴った糖尿病症例における半固形状流動食使用は血糖変動を適正化する-CGMを用いた半固形状流動食による血糖変動改善効果の検討-. 静脈経腸栄養 2017 ; 32 : 1361-1365.
 
8) Alish CJ, et al. A diabetes-specific enteral formula improves glycemic variability in patients with type 2 diabetes. Diabetes Technol Ther 2010 ; 12 : 419-425.
PubMed
9) American Diabetes Association. 15. Diabetes Care in the Hospital : Standards of Medical Care in Diabetes 2019. Diabetes Care 2019 ; 42 : S173-181.
PubMed
10) Cook A, et al. Evaluation of glycemic control using NPH insulin sliding scale versus insulin aspart sliding scale in continuously tube-fed patients. Nutr Clin Pract 2009 ; 24 : 718-722.
PubMed
11) Hsia E, et al. Comparison of 70/30 biphasic insulin with glargine/lispro regimen in non-critically ill diabetic patients on continuous enteral nutrition therapy. Nutr Clin Pract 2011 ; 26 : 714-717.
PubMed
P.179 掲載の参考文献
1) Anders A, et al. Bacterial phagocytosis and intracellular killing by alveolar macrophages in BB rats. Diabetes 1988 ; 37 : 544-549.
 
2) Mowat AG, et al. Chemotaxis of polymorphonuclear leukocytes from patients with diabetes mellitus. N Eng J Med 1970 ; 282 : 123-128.
 
3) Latham R, et al. The association of diabetes and glucose control with surgical-site infections among cardiothoracic surgery patients. Infect Control Hosp Epidemiol 2001 ; 22 : 607-612.
PubMed
4) Malmberg K, et al. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997 ; 314 : 1512-1515.
 
5) Van den Berghe G, et al. Intensive insulin therapy in crically ill patients. N Engl J Med 2001 ; 345 : 1359-1367.
PubMed
6) Van den Berghe G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006 ; 354 : 449-461.
PubMed
7) Van den Berghe G, et al. Intensive insulin therapy in mixed medical/surgical intensive care units : benefit versus harm. Diabetes 2006 ; 55 : 3151-3159.
PubMed
8) Finer S, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009 ; 360 : 1283-1297.
 
9) Van den Berghe G, et al. Intensive insulin therapy in critically ill patients : NICESUGAR or Leuven blood glucose target? J Clin Endocrinol Metab 2009 ; 94 : 3163-3170.
 
10) Preiser JC, et al. A prospective randomized multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units. Intensive Care Med 2009 ; 35 : 1738-1748.
PubMed
11) Wierner RS, et al. Benefits and risk of tight glucose control in critically ill adults : a meta-analysis. JAMA 2008 ; 300 : 933-944.
 
12) Donald EG, et al. Intensive insulin therapy and mortality among critically ill patients : a meta-analysis including NICE-SUGAR study data. CMAJ 2009 ; 180 : 821-827.
 
13) ACCORD Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008 ; 358 : 2545-2559.
 
14) ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008 ; 358 : 2560-2572.
 
15) Duckworth W, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009 ; 360 : 129-139.
PubMed
16) American Diabetes Association. 15. Diabetes Care in the Hospital : Standards of medical care in diabetes 2019.Diabetes Care 2019 ; 42 : S173-181.
PubMed
P.186 掲載の参考文献
1) 寺島秀夫, 他. 周術期を含め侵襲下におけるエネルギー投与に関する理論的考え方～既存のエネルギー投与量算定法からの脱却～. 静脈経腸栄養 2009 ; 24 : 1027-1043.
 
2) 日本集中治療医学会重症患者の栄養管理ガイドライン作成委員会. 委員会報告 日本版重症患者の栄養療法ガイドライン. 日集中医誌 2016 ; 23 : 185-281.
 
3) Pirat A, et al. Comparison of measured versus predicted energy requirements in critically ill cancer patients. Respir Care 2009 ; 54 : 487-494.
PubMed
4) 田中茂穂. Harris-Benedict式を使用する際に注意するべきことは? 臨床栄養 臨時増刊号 2015 ; 126 : 745-749.
 
5) 井上善文. 必要エネルギー量の算定-ストレス係数・活動係数は考慮すべきか? -静脈経腸栄養 2010 ; 2 : 573-579.
 
6) McClave SA, et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient : Society of critical care medicine SCCM) and American society for parenteral and enteral nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr 2009 ; 33 : 277-316.
 
7) http://www.nice.org.uk/
 
8) Casaer MP, et al. Early versus late parenteral nutrition in critically ill adults. N Engl J Med 2011 ; 365 : 506-517.
PubMed
9) 日本病態栄養学会. 日本病態栄養学会NSTガイドブック 2017 改定第5版. In : 宮澤靖 (編) : 栄養投与法の選択. pp32-39, 南江堂, 2017.
 
10) The American Society for Parenteral and Enteral Nutrition Board of Directors and the Clinical Guidelines Task Force : Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. JPEN J Parenter Enteral Nutr 2002 ; 26 : 1 SA-138SA.
 
11) Ukleja A, et al. Standards for nutrition support : adult hospitalized patients. Nutr Clin Pract 2010 ; 25 : 403-414.
PubMed

[III] がん化学療法中の血糖管理

P.195 掲載の参考文献
1) 笠山宗正. 合成グルココルチコイド. 日臨 2008 ; 66 : 119-124.
Medical*Online
2) Kawamori R, et al. Efficacy and safety of repaglinide vs nateglinide for treatment of Japanese patients with type 2 diabetes mellitus. J Diabetes Investig, 2012 ; 3 : 302-308.
PubMed
P.198 掲載の参考文献
1) Barone BB, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus : a systematic review and meta-analysis. JAMA 2008 ; 300 : 2754-2764.
PubMed
2) Brunello A, et al. Hyperglycemia during chemotherapy for hematologic and solid tumors is correlated with increased toxicity. Am J Clin Oncol 2011 ; 34 : 292-296.
PubMed
3) Gerards MC, et al. Impact of hyperglycemia on the efficacy of chemotherapy-A systematic review of preclinical studies. Crit Rev Oncol Hematol 2017 ; 113 : 235-241.
PubMed
4) Stein KB, et al. Colorectal cancer outcomes, recurrence, and complications in persons with and without diabetes mellitus : a systematic review and metaanalysis. Dig Dis Sci 2010 ; 55 : 1839-1851.
PubMed
5) Gold HT, et al. Treatment and outcomes in diabetic breast cancer patients. Breast Cancer Res Treat 2014 ; 143 : 551-570.
PubMed
P.202 掲載の参考文献
1) Nishimura A, et al. Efficacy and safety of repaglinide added to sitagliptin in Japanese patients with type 2 diabetes : a randomized 24 week open-label trial. Endocr J 2016 ; 63 : 1087-1098.
PubMed
P.206 掲載の参考文献
1) Citrome L, et al. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. Clin Drug Investig 2011 ; 31 : 455-482.
PubMed
2) 岡田俊, 他. 新規抗精神病薬服用中の統合失調症患者に対する代謝系副作用のモニタリング. 精神神経学雑誌 2008 ; 110 : 1209-1218.
 
3) Ozawa R, et al. The antipsychotic olanzapine induces apoptosis in insulinsecreting pancreatic β cells by blocking PERK-mediated translational attenuation. Cell Drug Funct 2013 ; 38 : 183-195.
 
4) Koller EA, et al. Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002 ; 22 : 841-852.
PubMed
5) ジプレキサ (オランザピン製剤) 特定項目製品情報概要, 日本標準商品分類番号 871179, 872391
 
P.217 掲載の参考文献
1) 日本糖尿病学会, 編. 糖尿病治療ガイド 2018-2019. pp77-80, 文光堂, 2018.
 
2) 日本糖尿病学会, 編. 糖尿病専門医研修ガイドブック. 改訂第7版, pp397-414, 診断と治療社, 2017.
 
3) 日本糖尿病療養指導士認定機構, 編著. 糖尿病療養指導ガイドブック 2017. 第1版, pp200-202, メディカルレビュー社, 2017.
 
4) SGLT 2 阻害薬の適正使用に関する委員会. SGLT 2 阻害薬の適正使用に関するRecommendation. 日本糖尿病学会, 2014.
 
5) 綿田裕考, 荒木栄一. 最新インスリン療法. 第2版, pp83-87, 中山書店, 2015.
 
6) 永田正男. 高齢者糖尿病のインスリン治療の原則と注意点. Geriatric Medicine, 2009.
Medical*Online
P.222 掲載の参考文献
1) Smith EM, et al. The total neuropathy score : a tool for measuring chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum. 2008 ; 35 : 96-102.
 
2) Vincenzi B, et al. Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. Support Care Cancer. 2013 ; 21 : 1313-1319.
PubMed
3) 日本がんサポーティブケア学会, 編. がん薬物療法に伴う末梢神経障害マネジメントの手引き 2017年版. pp31-43, 金原出版, 2017.
 
P.229 掲載の参考文献
1) Frank A, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007 ; 99 : 1232-1239.
 
2) Hatake K, et al. Bevacizumab safety in Japanese patients with colorectal cancer. Jpn J Clin Oncol 2016 ; 46 : 234-240.
PubMed
3) Zamorano JL, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines : The task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016 ; 37 : 2768-2801.
 
4) Izzedine H, et al. VEGF signaling inhibition-induce proteinuria : Mechanisms, significance and management. Eur J Cancer 2010 ; 46 : 439-448.
PubMed
5) Zhang ZF, et al. Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients : A systematic review and meta-analysis. PLoS One 2014 ; 9 : e90135.
PubMed
6) Tomita Y, et al. Key predictive factors of axitinib (AG-013736) -induced proteinuria and efficacy : A phase II study in Japanese patients with cytokine-refractory metastatic renal cell carcinoma. Eur J Cancer 2011 ; 47 : 2592-2602.
PubMed
P.232 掲載の参考文献
1) Meguro S, et al. Hypoglycemia detection rate differs among blood glucose monitoring sites. Diabetes Care. 2005 ; 28 : 708-709.
PubMed
P.238 掲載の参考文献
1) Hughes J, et al. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care 2015 ; 38 : e55-57.
PubMed
2) Martin-Liberal J, et al. Anti-programmed cell death-1 therapy and insulindependent diabetes : a case report. Cancer Immunol Immunother 2015 ; 64 : 765-767.
PubMed
3) Mellati M, et al. Anti-PD-1 and anti-PDL-1 monoclonal antibodies causing type 1 diabetes. Daibetes Care 2015 ; 38 : e137-138.
 
4) Gaudy C, et al. Anti-PD 1 pembrolizumab can induce exceptional fulminant type 1 diabetes. Diabetes Care 2015 ; 38 : e182-183.
 
5) 馬殿恵, 他. 抗PD-1抗体投与後に発症する1型糖尿病の特徴および臨床経過に関する調査報告. 糖尿病 2019 ; 62 : 37-46.
 
6) Saito D, et al. Detailed time course of decline in serum c-peptide levels in anti-programmed cell death-1 therapy-induced fulminant type 1 diabetes. Diabetes Care 2019 ; 42 : e40-41.
 
7) 今川彰久, 他. 1型糖尿病調査研究委員会報告-劇症1型糖尿病の新しい診断基準 (2012). 糖尿病 2012 ; 55 : 815-820.
 
P.245 掲載の参考文献
1) Intlekofer AM, et al. At the bench : preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol 2013 ; 94 : 25-39.
PubMed
2) Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012 ; 12 : 252-264.
PubMed
3) Ansari MJ, et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 2003 ; 198 : 63-69.
PubMed
4) Sharpe AH, et al. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 2007 ; 8 : 239-245.
PubMed
5) 馬殿恵, 他. 抗PD-1抗体投与後に発症する1型糖尿病の特徴および臨床経過に関する調査報告. 糖尿病 2019 ; 62 : 37-46.
 
6) 花房俊昭, 他. 劇症1型糖尿病調査研究委員会報告-疫学調査の解析と新基準の策定-. 糖尿病 2005 ; 48 : A 1 -A13.
 
7) 春日雅人, 他. 糖尿病と癌に関する委員会報告. 糖尿病 2013 ; 56 : 374-390.
 
8) 平田匠, 他. 1型糖尿病調査研究委員会 (劇症および急性発症1型糖尿病分科会) 報告-2型糖尿病経過中に劇症1型糖尿病様の発症様式を呈した症例の臨床的特性-. 糖尿病 2012 ; 55 : 505-511.
 
9) UK Prospective Diabetes Study 16. Overview of 6 years therapy of type II diabetes : a progressive disease. UK Prospective Diabetes Study Group. Diabetes 1995 ; 44 : 1243-1258.
 
10) 今川彰久, 他. 1型糖尿病調査研究委員会報告-劇症1型糖尿病の新しい診断基準 (2012). 糖尿病 2012 ; 55 : 815-820.
 
P.250 掲載の参考文献
1) Lee-Shing C, et al. Endocrine toxicity of cancer immunotherapy targeting immune Checkpoints. Endocr Rev 2019 ; 40 : 17-65.
 
2) 免疫チェックポイント阻害薬による内分泌障害の診療ガイドライン. 日本内分泌学会雑誌 2018 ; 94 : 1 -11.
 

[IV] がんサバイバー, 長期のがん治療が必要なケース

P.255 掲載の参考文献
1) 厚生労働省. 平成29年人口動態統計.
 
2) 国立がん研究センター. がん情報サービス. https://ganjoho.jp
 
3) 厚生労働省. 平成28年国民健康・栄養調査.
Medical*Online
4) 糖尿病と癌に関する委員会. 糖尿病と癌に関する委員会報告. 糖尿病 2013 ; 56 : 374-390.
 
5) 日本糖尿病学会, 編. 糖尿病診療ガイドライン 2016. 南江堂, 2016.
 
6) 日本老年医学会・日本糖尿病学会, 編. 高齢者糖尿病診療ガイドライン 2017. 南江堂, 2017.
 
7) Hasegawa T, et al. Long-term effect of alpha-glucosidase inhibitor on late dumping syndrome. J Gastroenterol Hepatol. 1998 ; 13 : 1201-1206.
PubMed
8) Fujita Y, et al. Successful treatment of reactive hypoglycemia secondary to late dumping syndrome using miglitol. Intern Med. 2012 ; 51 : 2581-2585.
PubMed
9) Kurihara K, et al. Effectiveness of sitagliptin in a patient with late dumping syndrome after total gastrectomy. Diabetes Metab Syndr. 2018 ; 12 : 203-206.
 
10) Chiappetta S, Stier C. A case report : Liraglutide as a novel treatment option in late dumping syndrome. Medicine 2017 ; 96 : 12-16.
PubMed
11) Heckman-Stoddard BM, et al. Repurposing metformin for the prevention of cancer and cancer recurrence. Diabetologia 2017 ; 60 : 1639-1647.
PubMed
12) Higurashi T, et al. Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes : a multicentre double-blind, placebo-controlled, randomised phase 3 trial. Lancet Oncol 2016 ; 17 : 475-483.
PubMed
13) Nanni O, et al. Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial. Breast Cancer Res Treat 2019 ; 174 : 433-442.
PubMed
14) Pimentel I, et al. A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy. Breast 2019 ; 48 : 17-23.
 
15) 日本糖尿病学会 ビ グ アナイド 薬の適正使用に関する委員会. メトホルミンの適正使用に関するRecommendation. 改訂2020年3月18日. [http://www.jds.or.jp/modules/important/index.php?content_id=20]
 
P.263 掲載の参考文献
1) 国立がん研究センター. がん情報サービス. https://ganjoho.jp
 
2) 日本糖尿病学会, 編. 糖尿病治療ガイド 2018-2019. 文光堂, 2018.
 
3) 福井道明. 前立腺がんの内分泌療法の代謝に及ぼす影響. Mebio 2018 ; 35 : 58-66.
Medical*Online
4) 笹岡利安, 他. エストロゲ ンと糖代謝. 糖尿病 2008 ; 59 : 829-832.
 
5) Wang H. et al. Androgen deprivation therapy is associated with diabetes : Evidence from meta-analysis. J Diabetes Investig 2016 ; 7 : 629-636.
PubMed
6) Saylor PJ, et al. Prostate cancer survivorship : prevention and treatment of the adverse effects of androgen deprivation therapy. J Gen Intern 2009 ; 24 : 389-394.
 
7) Buch K, et al. Effect of chemotherapy and aromatase inhibitors in the adjuvant treatment of breast cancer on glucose and insulin metabolism-A systematic review. Cancer Med 2019 ; 8 : 238-245.
PubMed
8) Santorelli ML. Hormonal therapy for breast cancer and diabetes incidence among postmenopausal women. Ann Epidemiol 2016 ; 26 : 436-440.
PubMed
9) Inaba M, et al. Marked hyperglycemia after androgen-deprivation therapy for prostate cancer and usefulness of pioglitazone for its treatment. Metabolism 2005 ; 54 : 55-59.
PubMed
10) Ahmadi H, Daneshmand S. Androgen deprivation therapy for prostate cancer : long-term safety and patient outcomes. Patient Relat Outcome Meas 2014 ; 5 : 63-70.
PubMed
P.282 掲載の参考文献
1) Rachel LD, et al. Antecedence hyperglycemia is associated with an increased risk of neutropenic infections during bone marrow transplantation. Diabetes Care 2008 ; 31 : 1972-1977.
 
2) 肥後直子, 他. がん治療中・後の2型糖尿病患者の血糖コントロールすることに対する考え方. 糖尿病 2015 ; 58 : 183-191.
 
3) 小澤竹俊. 緩和ケア読本. pp43-72, 日本医事新報社, 2012.
 
4) 山崎真裕, 他. 糖尿病をもつ終末期がん患者の血糖コントロールの意味を考えさせられた1例-糖尿病医療学から考える-. 糖尿病医療学 2018 ; 1 : 35-40.
 

書評

最近チェックした商品履歴

Loading...